Related Experiment Video
Updated: Jun 4, 2025
Signal Acquisition, Score Interpretation, and Economics of a Non-Invasive Point-of-Care Test for Coronary Artery Disease
Published on: August 9, 2024
Proposed Utilization of PlGF-Based Diagnostic Testing for Suspected Preeclampsia in Québec: Insights From an Expert
Isabelle Malhamé1, Suzanne Demers2, Véronica Moramarco3
1Department of Medicine, McGill University Health Centre, Montreal, QC; Centre for Outcomes Research and Evaluation, Research Institute of the McGill University Health Centre, Montreal, QC.
Prompt diagnosis of preeclampsia is key to ensure appropriate management and reduce associated adverse outcomes. Placental growth factor (PlGF)-based biomarkers have been shown to be safe and effective diagnostic tools for preterm preeclampsia, and their use is recommended by most recent Canadian guidelines. The present report summarizes an expert panel discussion that led to the development of a proposed utilization algorithm for PlGF-based diagnostic testing for suspected preeclampsia in Québec. In addition to recommendations on who, why, when to test and how to interpret and respond to the test, considerations for optimizing clinical testing relevance were suggested.
Prompt diagnosis of preeclampsia is key to ensure appropriate management and reduce associated adverse outcomes. Placental growth factor (PlGF)-based biomarkers have been shown to be safe and effective diagnostic tools for preterm preeclampsia, and their use is recommended by most recent Canadian guidelines. The present report summarizes an expert panel discussion that led to the development of a proposed utilization algorithm for PlGF-based diagnostic testing for suspected preeclampsia in Québec. In addition to recommendations on who, why, when to test and how to interpret and respond to the test, considerations for optimizing clinical testing relevance were suggested.
